MedPath

The effect of cannabidiol (40mg) on fear conditioning

Completed
Conditions
anxiety disorders
pathological fear
10002861
Registration Number
NL-OMON42213
Lead Sponsor
niversiteit Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
48
Inclusion Criteria

- Male or female volunteers between 18 and 40 years.
- Judged to be in good physical and mental health on the basis of the
medical history according to self-report.
- Have a normal binocular acuity, corrected or uncorrected.
- Female participants must declare they are on reliable birth control.

Exclusion Criteria

- Have a history of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study.
- Present any other conditions in that in the investigators*, the subjects* personal or the physicians* opinion may confound the results of the study.
- History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis.
- Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study.
- Current respiratory disease or history of respiratory disease.
- Current asthma or history of asthma.
- Acute cardiac disease and/or history of cardiac disease.
- Known hypersensitivity to CBD.
- Exposed to cannabinoids with adverse reactions.
- Have a history of severe allergy or general drug hypersensitivity.
- History of abuse or current regular use of cannabis more than once a week.
- Have been using psychoactive drugs in the four weeks prior to the study.
- Current use of drugs of abuse or indications, from urine screening, of current use of drugs of abuse
- History of epilepsy.
- Pregnancy, i.e., a positive β-HCG urine test.
- Lactating.
- Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Fear as reflected in the EMG and as reflected in answers on a VAS during a<br /><br>passive VR navigation task (see protocol [C1] for details).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>SCR (Skin conductance response)</p><br>
© Copyright 2025. All Rights Reserved by MedPath